These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16044146)

  • 1. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Tey S; Butler J; Durrant S; Hill G; Morton J; Kennedy G
    Bone Marrow Transplant; 2005 Sep; 36(6):553-4; author reply 554. PubMed ID: 16044146
    [No Abstract]   [Full Text] [Related]  

  • 2. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Hahn T; Benekli M; Wong C; Moysich KB; Hyland A; Michalek AM; Alam A; Baer MR; Bambach B; Czuczman MS; Wetzler M; Becker JL; McCarthy PL
    Bone Marrow Transplant; 2005 Mar; 35(6):557-66. PubMed ID: 15665852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
    Sureda A
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis.
    Perry AR; Peniket AJ; Watts MJ; Leverett D; Goldstone AH; Linch DC
    Br J Haematol; 1999 Apr; 105(1):280-7. PubMed ID: 10233395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
    Claviez A; Sureda A; Schmitz N
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
    Kasamon YL; Jones RJ; Diehl LF; Nayer H; Borowitz MJ; Garrett-Mayer E; Ambinder RF; Abrams RA; Zhang Z; Flinn IW
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):39-46. PubMed ID: 15625543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of hematopoietic stem cell transplantation in advanced Hodgkin Lymphoma.
    Seftel M; Rubinger M
    Transfus Apher Sci; 2007 Aug; 37(1):49-56. PubMed ID: 17716946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
    Ballova V; Ladicka M; Vranovsky A; Lakota J
    Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome following autologous and allogeneic blood and marrow transplantation for relapsed diffuse large-cell non-Hodgkin's lymphoma.
    Aksentijevich I; Jones RJ; Ambinder RF; Garrett-Mayer E; Flinn IW
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):965-72. PubMed ID: 16920563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
    Dean RM; Fowler DH; Wilson WH; Odom J; Steinberg SM; Chow C; Kasten-Sportes C; Gress RE; Bishop MR
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):593-9. PubMed ID: 16041309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America.
    Passweg JR; Rowlings PA; Armitage JO; Gale RP; Pelz CJ; Sobocinski KA; Klein JP; Zhang MJ; Horowitz MM
    Clin Transpl; 1995; ():117-27. PubMed ID: 8794259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells in autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma: graft content and post transplant recovery predict survival.
    Dean R; Masci P; Pohlman B; Andresen S; Serafino S; Sobecks R; Kuczkowski E; Curtis J; Maciejewski J; Rybicki L; Kalaycio M; Hsi E; Theil K; Bolwell BJ
    Bone Marrow Transplant; 2005 Dec; 36(12):1049-52. PubMed ID: 16247431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell transplantation in Hodgkin lymphoma.
    Murphy F; Sirohi B; Cunningham D
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):297-306. PubMed ID: 17338650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.